Dr. Jarushka Naidoo - Why Did You Choose To Study Lung Cancer

Dr. Jarushka Naidoo - Why did you choose to study lung cancer?

Lung Cancer Foundation of America

Dr Jarushka Naidoo answers your lung cancer questions

Irish Cancer Society

Lung cancer and immunotherapy with Prof Jarushka Naidoo

Irish Cancer Society

Dr. Naidoo on Studies of Immune-Related Adverse Events in Lung Cancer

Dr. Naidoo on the Mechanisms Behind Immune-Related Adverse Events in Lung Cancer

Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

Dr Jarushka Naidoo:v3 Revolutions in Lung Cancer Research

Lung Cancer Foundation of America

Dr Jarushka Naidoo: Why Patient Interaction is so Important

Lung Cancer Foundation of America

Metastatic Non-Small Cell Lung Cancer (NSCLC) Algorithm w/ Targetable Mutations- Dr. Jarushka Naidoo

OncBrothers: Practice-Changing Cancer Discussions

Dr. Triparna Sen: Why did you choose lung cancer research?

Lung Cancer Foundation of America

BTOG 2021 highlights: translational research in lung cancer

Dr. Naidoo on Considerations for Managing irAEs in NSCLC

Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC

Dr Jarushka Naidoo LCFA Funded Investigator

Lung Cancer Foundation of America

Dr. Alexander Spira Discusses Advances in Non-Small Cell Lung Cancer (NSCLC)

J&J Innovative Medicine

Dr Jarushka Naidoo Discusses Evolution of Biomarker Testing

Dr. Naidoo on Treating Immune-Related Adverse Events in NSCLC

Copy of Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC

Unanswered questions regarding the use of IO in NSCLC

The ICLIO Visiting Experts Program